Top

Gut Pathogens

Published in:

Open Access 01-12-2022 | Obesity | Research

Grape seed and skin extract, a potential prebiotic with anti-obesity effect through gut microbiota modulation

Authors: Mohamed Mokrani, Kamel Charradi, Ferid Limam, Ezzedine Aouani, Maria C. Urdaci

Published in: Gut Pathogens | Issue 1/2022

Abstract

Background

Obesity is a worldwide health problem and a significant risk factor for diabetes and cardiovascular diseases. Gut microbiota (GM) plays an essential role in obesity, and prebiotics such as polyphenols could be one way to improve microbial dysbiosis-induced obesity.

Objective

This study was designed to assess the effectiveness of grape seed and skin extract (GSSE), and/or orlistat on obese rats fed with high fat diet by targeting GM modulations. The impact of treatments was also studied in non-obese rats.

Material and methods

Rats were rendered obese or kept with a standard diet for three months. Then they were treated either with GSSE or orlistat or with the combined treatment (GSOR) during three months and then sacrificed. Adipose tissues, blood and faeces were collected and analyzed.

Results

In obese rats and to a lesser extent in non-obese rats, treatments decreased the weight of various adipose tissues and the serum levels of cholesterol, LDL, triglycerides, lipase, and CRP and increased HDL and adiponectin. GSOR treatment was even more efficient that orlistat. Obese rats had less GM diversity than non-obese rats and orlistat reduced it even more. However, diversity was restored with GSSE and GSOR treatments. Potential pathogenic Streptococcus alactolyticus/gallolyticus species were greatly increased in obese rats and drastically reduced with the treatments, as wells as other potential pathobionts.

Conclusions

GSSE exerts beneficial effects in obese rats and restores, at least partially, the observed dysbiosis. GSOR induced the highest beneficial effect. Moreover, the various treatments could also enhance physiological and GM modifications in non obese rats.

Available only for authorised users

Vandevijvere S, Chow CC, Hall KD, Umali E, Swinburn BA. Increased food energy supply as a major driver of the obesity epidemic: a global analysis. Bull World Health Organ. 2015;93:446–56.PubMedPubMedCentralCrossRef

World Health Organization (WHO). World Health Organization (WHO). 2020. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

NCD-Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387:1377–96.CrossRef

El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: challenges and call for action. World J Diabetes. 2021;12:1401–25.PubMedPubMedCentralCrossRef

Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH, et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020;11:1–29.CrossRef

Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107. https://doi.org/10.1038/nri2925.CrossRefPubMed

Bedhiafi T, Charradi K, Ben Azaiz M, Mahmoudi M, Msakni I, Jebari K, et al. Supplementation of grape seed and skin extract to orlistat therapy prevents high-fat diet-induced murine spleen lipotoxicity. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2018. https://doi.org/10.1139/apnm-2017-0743.CrossRef

Manor O, Dai CL, Kornilov SA, Smith B, Price ND, Lovejoy JC, et al. Health and disease markers correlate with gut microbiome composition across thousands of people. Nat Commun. 2020;11:1–12. https://doi.org/10.1038/s41467-020-18871-1.CrossRef

Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013;11:639–47. https://doi.org/10.1038/nrmicro3089.CrossRefPubMed

10.

Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1–10.PubMedCrossRef

11.

Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol. 2016;34:4270–6.PubMedPubMedCentralCrossRef

12.

Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8:1–12. https://doi.org/10.1186/s13073-016-0303-2.CrossRef

13.

Cani PD, Bibiloni R, Knauf C, Neyrinck AM, Delzenne NM. Changes in gut microbiota control metabolic diet–induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81.PubMedCrossRef

14.

Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19:55–71. https://doi.org/10.1038/s41579-020-0433-9.CrossRefPubMed

15.

Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23:107–13. https://doi.org/10.1038/nm.4236.CrossRefPubMed

16.

Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65:426–36.PubMedCrossRef

17.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.PubMedCrossRef

18.

Mocanu V, Zhang Z, Deehan EC, Kao DH, Hotte N, Karmali S, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med. 2021;27:1272–9. https://doi.org/10.1038/s41591-021-01399-2.CrossRefPubMed

19.

Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–80. https://doi.org/10.1038/nature09944.CrossRefPubMedPubMedCentral

20.

Le Barz M, Anhê FF, Varin TV, Desjardins Y, Levy E, Roy D, et al. Probiotics as complementary treatment for metabolic disorders. Diabetes Metab J. 2015;39:291–303.PubMedPubMedCentralCrossRef

21.

Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbial gene richness. Nature 2013;500:585–8. http://www.nature.com/articles/nature12480

22.

Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14:491–502. https://doi.org/10.1038/nrgastro.2017.75.CrossRefPubMed

23.

Anhê FF, Varin TV, Le Barz M, Desjardins Y, Levy E, Roy D, et al. Gut microbiota dysbiosis in obesity-linked metabolic diseases and prebiotic potential of polyphenol-rich extracts. Curr Obes Rep. 2015;4:389–400.PubMedCrossRef

24.

Alves-Santos AM, Sugizaki CSA, Lima GC, Naves MMV. Prebiotic effect of dietary polyphenols: a systematic review. J Funct Foods. 2020;74:104169. https://doi.org/10.1016/j.jff.2020.104169.CrossRef

25.

Dudonné S, Varin TV, Forato Anhê F, Dubé P, Roy D, Pilon G, et al. Modulatory effects of a cranberry extract co-supplementation with Bacillus subtilis CU1 probiotic on phenolic compounds bioavailability and gut microbiota composition in high-fat diet-fed mice. PharmaNutrition. 2015;3:89–100. https://doi.org/10.1016/j.phanu.2015.04.002.CrossRef

26.

Cheah KY, Bastian SEP, Acott TMV, Abimosleh SM, Lymn KA, Howarth GS. Grape seed extract reduces the severity of selected disease markers in the proximal colon of dextran sulphate sodium-induced colitis in rats. Dig Dis Sci. 2013;58:970–7.PubMedCrossRef

27.

Charradi K, Mahmoudi M, Bedhia T, Kadri S. ScienceDirect Dietary supplementation of grape seed and skin flour mitigates brain oxidative damage induced by a high-fat diet in rat: gender dependency. Biomed Pharmacother. 2017;87:519–26.PubMedCrossRef

28.

Mahmoudi M, Charradi K, Limam F, Aouani E. Grape seed and skin extract as an adjunct to xenical therapy reduces obesity, brain lipotoxicity and oxidative stress in high fat diet fed rats. Obes Res Clin Pract. 2018;12:115–26.PubMedCrossRef

29.

Kadri S, El Ayed M, Cosette P, Jouenne T, Elkhaoui S, Zekri S, et al. Neuroprotective effect of grape seed extract on brain ischemia: a proteomic approach. Metab Brain Dis. 2019;34:889–907.PubMedCrossRef

30.

Ke J, An Y, Cao B, Lang J, Wu N, Zhao D. Orlistat-induced gut microbiota modification in obese mice. Evid Based Complement Altern Med. 2020;2020:1–9.CrossRef

31.

Orlistat (marketed as Alli and Xenical) Information | FDA [Internet]. [cited 2022 Feb 23]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/orlistat-marketed-alli-and-xenical-information

32.

Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31:53–65.PubMedCrossRef

33.

Mokni M, Hamlaoui S, Kadri S, Limam F, Amri M, Marzouki L, et al. Efficacy of grape seed and skin extract against doxorubicin-induced oxidative stress in rat liver. Pak J Pharm Sci. 2015;28:1971–8.PubMed

34.

Escudié F, Auer L, Bernard M, Mariadassou M, Cauquil L, Vidal K, et al. FROGS: find, rapidly, OTUs with galaxy solution. Bioinformatics (Oxford, England). 2018;34:1287–94.CrossRef

35.

Volant S, Lechat P, Woringer P, Motreff L, Campagne P, Malabat C, et al. Open Access SHAMAN : a user-friendly website for metataxonomic analysis from raw reads to statistical analysis. BMC Bioinform. 2020. https://doi.org/10.1186/s12859-020-03666-4.CrossRef

36.

Janda MW. The genus streptococcus—part i: emerging pathogens in the “Pyogenic Cocci” and the “Streptococcus bovis. Groups Clin Microbiol Newslett. 2014;36(20):157–66.CrossRef

37.

Jiao X, Wang Y, Lin Y, Lang Y, Li E, Zhang X, et al. Blueberry polyphenols extract as a potential prebiotic with anti-obesity effects on C57BL/6J mice by modulating the gut microbiota. J Nutr Biochem. 2019;64:88–100.PubMedCrossRef

38.

Ke X, Walker A, Haange SB. Synbiotic-driven improvement of metabolic disturbances is associated with changes in the gut microbiome in diet-induced obese mice. Mol Metab. 2019;22:96–109.PubMedPubMedCentralCrossRef

39.

Collins B, Hoffman J, Martinez K, Grace M, Lila MA, Cockrell C, et al. A polyphenol-rich fraction obtained from table grapes decreases adiposity, insulin resistance and markers of inflammation and impacts gut microbiota in high-fat-fed mice. J Nutr Biochem. 2016;31:150–65. https://doi.org/10.1016/j.jnutbio.2015.12.021.CrossRefPubMedPubMedCentral

40.

Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, et al. A taxonomic signature of obesity in a large study of American adults. Sci Rep. 2018. https://doi.org/10.1038/s41598-018-28126-1.CrossRefPubMedPubMedCentral

41.

Zeng H, Ishaq SL, Zhao FQ, Wright ADG. Colonic inflammation accompanies an increase of β-catenin signaling and Lachnospiraceae/Streptococcaceae bacteria in the hind gut of high-fat diet-fed mice. J Nutr Biochem. 2016;35:30–6.PubMedCrossRef

42.

Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J. 2013;7:880–4.PubMedCrossRef

43.

Boer CG, Radjabzadeh D, Medina-Gomez C, Garmaeva S, Schiphof D, Arp P, et al. Intestinal microbiome composition and its relation to joint pain and inflammation. Nat Commun. 2019;10:4881.PubMedPubMedCentralCrossRef

44.

Takewaki D, Yamamura T. Gut microbiome dysbiosis shapes disease course in the different stages of multiple sclerosis. Clin Exp Neuroimmunol. 2021;12:87–8.CrossRef

45.

Dekker JP, Lau AF. An update on the Streptococcus bovis group: classification, identification, disease associations. J Clin Microbiol. 2014;54(7):1694–9.CrossRef

46.

Pasquereau-Kotula E, Martins M, Aymeric L, Dramsi S. Significance of Streptococcus gallolyticus subsp. gallolyticus association with colorectal cancer. Front Microbiol. 2018;9:614.PubMedPubMedCentralCrossRef

47.

Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020;71(10):2669–78.PubMedCrossRef

48.

Nguyen TLA, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Models Mech 2015;8:1–16. https://journals.biologists.com/dmm/article/8/1/1/3621/How-informative-is-the-mouse-for-human-gut

49.

Nguyen QV, Chong LC, Hor Y-Y, Lew L-C, Rather IA, Choi S-B. Role of probiotics in the management of COVID-19: a computational perspective. Nutrients. 2022;14:274.PubMedPubMedCentralCrossRef

50.

Zuo T, Liu Q, Zhang F, Lui GC-Y, Tso EYK, Yeoh YK, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 70:276.

51.

Augusti PR, Conterato GMM, Denardin CC. Bioactivity, bioavailability, and gut microbiota transformations of dietary phenolic compounds: implications for COVID-19. J Nutr Biochem. 2021;97:108787.PubMedPubMedCentralCrossRef

52.

Santos J, Ribeiro M, Gambero A. The impact of polyphenols-based diet on the inflammatory profile in COVID-19 elderly and obese patients. Integr Physiol. 2021;11:612268.

53.

Clavel T, Desmarchelier C, Haller D, Gérard P, Rohn S, Lepage P. Intestinal microbiota in metabolic diseases: from bacterial community structure and functions to species of pathophysiological relevance. Gut Microbes. 2014;5:544–51.PubMedCrossRef

54.

Gallardo-Becerra L, Cornejo-Granados F, García-López R. Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children. Microb Cell Fact. 2020;19:1–18.CrossRef

55.

Martínez I, Muller CE, Walter J. Long-term temporal analysis of the human fecal microbiota revealed a stable core of dominant bacterial species. PLoS ONE. 2013;8:e69621.PubMedPubMedCentralCrossRef

56.

Bangsgaard Bendtsen KM, Krych L, Sørensen DB, Pang W, Nielsen DS, Josefsen K. Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. PLoS ONE. 2012;7:46231.CrossRef

57.

Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv. 2019;5(2):eaau8317.PubMedPubMedCentralCrossRef

58.

Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, et al. A step ahead: exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode. Bipolar Disord. 2019;21:40–9.PubMedCrossRef

59.

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:60.CrossRef

60.

Kim KA, Gu W, Lee IA. High fat diet induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS ONE. 2012;7:e47713.PubMedPubMedCentralCrossRef

61.

Rettedal E, Vilain S, Lindblom S, Lehnert K, Scofield C, George S, et al. Alteration of the ileal microbiota of weanling piglets by the growth-promoting antibiotic chlortetracycline. Appl Environ Microbiol. 2019;75:5489–95.CrossRef

62.

Kang X, Zhan L, Lu X, Song J, Zhong Y, Wang Y. Characteristics of gastric microbiota in GK rats with spontaneous diabetes: a comparative study. Diabetes Metab Syndr Obes. 2020;13:1435–47.PubMedPubMedCentralCrossRef

63.

Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS ONE. 2009;4:1–8.CrossRef

64.

Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes. 2020;12:1802866.PubMedPubMedCentralCrossRef

65.

Wang S, Huang M, You X, Zhao J, Chen L, Wang L, et al. Gut microbiota mediates the anti-obesity effect of calorie restriction in mice. Sci Rep. 2018;8:2–15. https://doi.org/10.1038/s41598-018-31353-1.CrossRef

66.

Mazier W, Le Corf K, Martinez C, Tudela H, Kissi D, Kropp C, et al. A new strain of Christensenella minuta as a potential biotherapy for obesity and associated metabolic diseases. Cells. 2021;10:823.PubMedPubMedCentralCrossRef

67.

Ye J, Zhao Y, Chen X, Zhou H, Yang Y, Zhang X, et al. Pu-erh tea ameliorates obesity and modulates gut microbiota in high fat diet fed mice. Food Res Int. 2021;144:0963–9969.CrossRef

68.

Corcoran BM, Stanton C, Fitzgerald GF, Ross RP, P Ross PaulRoss CR. Growth of probiotic lactobacilli in the presence of oleic acid enhances subsequent survival in gastric juice. http://mic.sgmjournals.org

69.

Lee SY, Yu J, Ahn KM, Kim KW, Shin YH, Lee KS, et al. Additive effect between IL-13 polymorphism and cesarean section delivery/prenatal antibiotics use on atopic dermatitis: a birth cohort study (COCOA). PLoS ONE. 2014;9:e96603.PubMedPubMedCentralCrossRef

70.

Jang HR, Park HJ, Kang D, Chung H, Nam MH, Lee Y, et al. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. Exp Mol Med. 2019;51:1–14.PubMed

71.

Plamada D, Cristian VD. Polyphenols-gut microbiota interrelationship: a transition to a new generation of prebiotics. Nutrients. 2021. https://doi.org/10.3390/nu14010137.CrossRefPubMedPubMedCentral

72.

Daisley BA, Koenig D, Engelbrecht K, Doney L, Hards K, Al KF, et al. Emerging connections between gut microbiome bioenergetics and chronic metabolic diseases. Cell Rep. 2021. https://doi.org/10.1016/j.celrep.2021.110087.CrossRefPubMed

73.

Stadlbauer V, Engertsberger L, Komarova I, Feldbacher N, Leber B, Pichler G, et al. Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study. BMC Geriatr. 2020;20:1–13. https://doi.org/10.1186/s12877-020-01644-2.CrossRef

74.

Lee SM, Han HW, Yim SY. Beneficial effects of soy milk and fiber on high cholesterol diet-induced alteration of gut microbiota and inflammatory gene expression in rats. Food Funct. 2015;6:492–500.PubMedCrossRef

75.

Kelly TN, Bazzano LA, Ajami NJ, He H, Zhao J, Petrosino JF, et al. Gut microbiome associates with lifetime cardiovascular disease risk profile among Bogalusa heart study participants. Circ Res. 2016;119:956–64. https://doi.org/10.1161/CIRCRESAHA.116.309219.CrossRefPubMedPubMedCentral

76.

Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol. 2016;7:1081.PubMedPubMedCentralCrossRef

77.

Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, et al. Differences in gut microbiota associated with age, sex, and stool consistency in healthy Japanese subjects. J Gastroenterol. 2019;54:53–63.PubMedCrossRef

78.

Chung Y, Ryu Y, An BC, Yoon YS, Choi O, Kim TY, et al. A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota. Microbiome. 2021;9:1–17. https://doi.org/10.1186/s40168-021-01071-4.CrossRef

79.

Charradi K, Elkahoui S, Karkouch I, Limam F, Ben Hassine F, El May MV, et al. Protective effect of grape seed and skin extract against high-fat diet-induced liver steatosis and zinc depletion in rat. Dig Dis Sci. 2014;59(8):1768–78.PubMedCrossRef

80.

Humbert G, Guingamp MF, Linden G. Method for the measurement of lipase activity in milk. J Dairy Res. 1997;64:465–9.PubMedCrossRef

Title: Grape seed and skin extract, a potential prebiotic with anti-obesity effect through gut microbiota modulation
Authors: Mohamed Mokrani
Kamel Charradi
Ferid Limam
Ezzedine Aouani
Maria C. Urdaci
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Obesity
Obesity
Streptococci
Respiratory Microbiota
Published in: Gut Pathogens / Issue 1/2022
Electronic ISSN: 1757-4749
DOI: https://doi.org/10.1186/s13099-022-00505-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Material and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Role of fecal calprotectin as a hypoxic intestinal damage biomarker in COVID-19 patients

Amoxicillin modulates gut microbiota to improve short-term high-fat diet induced pathophysiology in mice

Genomic characteristics and comparative genomics of Salmonella enterica subsp. enterica serovar Schwarzengrund strain S16 isolated from chicken feces

Closely related Salmonella Derby strains triggered distinct gut microbiota alteration

Genomic insights into zoonotic transmission and antimicrobial resistance in Campylobacter jejuni from farm to fork: a one health perspective

Obesity is not associated with adverse outcomes among hospitalized patients with Clostridioides difficile infection

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage